Josephine Sheedy

发表

Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia

B. Ray, J. Colacino, A. Branstrom, 2022, Frontiers in Oncology.

BMI1 as a novel target for drug discovery in cancer

T. Davis, Josephine Sheedy, M. Weetall, 2011, Journal of cellular biochemistry.

BMI1 is a therapeutic target in recurrent medulloblastoma

B. Doble, Yoon-Jae Cho, H. Farooq, 2018, Oncogene.

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

S. Peltz, A. Jacobson, T. Davis, 2018, Molecular Cancer Therapeutics.

Radiotherapy of human xenograft NSCLC tumors in nude mice with a 90Y-labeled anti-tissue factor antibody.

M. Berger, Qifeng Yang, Josephine Sheedy, 2005, Cancer biotherapy & radiopharmaceuticals.

4-Hydroxy-2-pyridones: Discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis.

J. Narasimhan, A. Branstrom, Josephine Sheedy, 2017, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy.

J. Narasimhan, Song Huang, Josephine Sheedy, 2016, Journal of medicinal chemistry.

Nonsense Suppression Approaches in Treating Hemophilia

P. Margaritis, K. High, Josephine Sheedy, 2008 .

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Ramesh Kakarla, Guangming Chen, Song Huang, 2014, Journal of medicinal chemistry.

Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform

Jean Hedrick, S. Peltz, T. Davis, 2016, PloS one.

The nucleoside analog clitocine is a potent and efficacious readthrough agent.

S. Peltz, T. Davis, J. Leszyk, 2017, RNA.

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential

S. Peltz, Jairo L. Sierra, H. Ren, 2018, PloS one.

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.

A. Miyawaki, A. Iwama, S. Yamazaki, 2021, Blood advances.

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent

M. Steinmetz, A. Prota, M. Pykett, 2021, Molecular Cancer Therapeutics.

SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy

Anirvan Ghosh, Roland Schmucki, Hasane Ratni, 2014, Science.

SMN protein is required throughout life to prevent spinal muscular atrophy disease progression.

F. Metzger, J. Narasimhan, Josephine Sheedy, 2021, Human molecular genetics.

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

F. Metzger, S. Paushkin, L. Pellizzoni, 2016, Human molecular genetics.

The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells

A. Iwama, K. Yokote, C. Nakaseko, 2021, Scientific Reports.

Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma

Stephen A. Sastra, Carmine F. Palermo, K. Olive, 2019, Clinical Cancer Research.

Chemical modifications of G418 (geneticin): Synthesis of novel readthrough aminoglycosides results in an improved in vitro safety window but no improvements in vivo.

Jairo L. Sierra, A. Branstrom, Josephine Sheedy, 2020, Carbohydrate research.

Efficacy of Tubulin Polymerization Inhibitor in Myelodysplastic Syndrome

A. Iwama, Josephine Sheedy, M. Weetall, 2020 .

Efficacy of the novel tubulin polymerization inhibitor PTC‐028 for myelodysplastic syndrome

A. Miyawaki, Y. Furukawa, A. Iwama, 2020, Cancer science.

Abstract 5517: PTC596-induced Bmi1 hyper-phosphorylation via Cdk1/2 activation resulting in tumor stem cell depletion

T. Davis, J. Colacino, Josephine Sheedy, 2014 .

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent

J. Colacino, A. Branstrom, B. Furia, 2021, Molecular Cancer Therapeutics.